Table 1: Patients with anti-resorptive agents-related osteonecrosis of the jaw (ARONJ).
Main department of treatment Main disease Number of the days from administration start date to diagnosis Administered drug Administration after diagnosis of ARONJ Surgical procedure before administration of drug Conservative therapy Surgery
Department of Allergy and Respiratory Medicine Lung cancer 188 Zoledronic acid Discontinuation None o o
Department of Hematology and Oncology Myelodysplastic syndrome 1318 Risedronate Continuation None
Department of Cardiovascular Medicine Aortic stenosis Hypertrophic cardiomyopathy 365 Alendronate Discontinuation Tooth extraction o
Breast and Endocrine Surgery Department Breast cancer 408 Zoledronic acid Continuation Tooth extraction o
Department of Allergy and Respiratory Medicine Lung cancer 92 Denosumab Continuation Tooth extraction o
Gastroenterology and Hepatology Department Liver cancer 175 Zoledronic acid Continuation Tooth extraction o
Urology Prostatic cancer 2650 Zoledronic acid None Tooth extraction o
Digestive tract surgery Colorectal cancer 574 Zoledronic acid Continuation Tooth extraction o
Department of Allergy and Respiratory Medicine Breast cancer 1540 Zoledronic acid Continuation None o
Breast and Endocrine Surgery Department Breast cancer 65 Denosumab Continuation Tooth extraction o
Department of Allergy and Respiratory Medicine Lung cancer 1071 Zoledronic acid Denosumab Continuation None o
Breast and Endocrine Surgery Department Breast cancer 1086 Zoledronic acid Denosumab Continuation None o
Department of Allergy and Respiratory Medicine Kidney cancer 186 Denosumab Continuation Tooth extraction o
Breast and Endocrine Surgery Department Breast cancer 2582 Zoledronic acid Continuation None 0